Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Intangibles (2022 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Intangibles for 4 consecutive years, with $25.2 million as the latest value for Q4 2025.

  • Quarterly Intangibles changed 0.0% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $25.2 million for FY2025, 0.0% changed from the prior year.
  • Intangibles hit $25.2 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $25.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $25.7 million in Q4 2022 to a low of $25.2 million in Q3 2023.
  • Historically, Intangibles has averaged $25.3 million across 4 years, with a median of $25.2 million in 2023.
  • Biggest five-year swings in Intangibles: dropped 2.23% in 2023 and later changed 0.0% in 2024.
  • Year by year, Intangibles stood at $25.7 million in 2022, then fell by 2.23% to $25.2 million in 2023, then changed by 0.0% to $25.2 million in 2024, then changed by 0.0% to $25.2 million in 2025.
  • Business Quant data shows Intangibles for RCKT at $25.2 million in Q4 2025, $25.2 million in Q3 2025, and $25.2 million in Q2 2025.